^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A prospective, multi-center, real-world study of apatinib mesylate in the treatment of gastric cancer
Excerpt:
...Patients with HER2 negative gastric or gastroesophageal junction adenocarcinoma confirmed by histology or cytology; 3. ...
Trial ID:
Source:
Title:
A prospective study of apatinib plus concurrent neoadjuvant chemoradiotherapy for Siewert II, III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction
Excerpt:
...Confirmed to Siewert II, III of locally advanced adenocarcinoma at gastroesophageal junction and tumor long diameter ≤8 cm by gastroscopy and CT, The her-2 negative was detected by immunohistochemistry; 3. ...
Trial ID:
More C2 evidence
Source:
Title:
A prospective, randomized, controlled, multicenter, phase III study of apatinib plus concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction
Excerpt:
...The her-2 negative was detected by immunohistochemistry or fluorescence in situ hybridization; 3. ...
Trial ID:
Source:
Title:
Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer
Excerpt:
...- Negative HER-2 state...
Trial ID:
Source:
Title:
A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction
Excerpt:
...Confirmed to Siewert II , III of locally advanced adenocarcinoma at gastroesophageal junction and tumor long diameter ≤8 cm by gastroscopy and CT, The her-2 negative was detected by immunohistochemistry; 3....
Trial ID:
Source:
Title:
Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction
Excerpt:
...The her-2 negative was detected by immunohistochemistry or fluorescence in situ hybridization; 3....
Trial ID:
Source:
Title:
Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer
Excerpt:
...Patients were tested for tumor HER2 status before treatment, and patients with HER2-negative disease； 6....
Trial ID:
Source:
Title:
A Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in ELM Gastric Cancer
Excerpt:
...- Negative HER-2 state...
Trial ID:
Less C2 evidence
Source:
Title:
A retrospective cohort study examining the effects of anti–PD-1 antibody in combination with apatinib in patients previously treated for HER2-negative advanced gastric/gastroesophageal junction cancer.
Published date:
05/25/2023
Excerpt:
This retrospective study included consecutive patients who received a programmed cell death protein 1 (PD-1) inhibitor plus the VEGFR-2 inhibitor apatinib...histologically-proven, human epidermal growth factor receptor 2 (HER2)-negative G/GEJ cancer....The objective response rate was 15.4% (95% confidence interval [CI] 6.9–28.1), the disease control rate was 61.5% (95% CI 47.0–74.7)...median progression-free survival was 4.2 months (95% CI 2.6–4.8), overall survival was 9.3 months (95% CI 7.9–12.9)....Combination therapy with an anti-PD-1 antibody and apatinib was effective in patients with previously treated, unresectable advanced or metastatic G/GEJ cancer, with a manageable safety profile.
Secondary therapy:
Undisclosed PD-1 inhibitor
DOI:
10.1200/JCO.2023.41.16_suppl.e16048
Source:
Title:
Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer
Published date:
06/15/2021
Excerpt:
Previously untreated patients with unresectable HER-2-negative advanced gastric cancer were selected….All the patients received six cycles of S-1 and oxaliplatin and five cycles of apatinib, which were administered at intervals of three weeks….Apatinib combined with oxaliplatin and S-1 showed good short-term survival...
Secondary therapy:
oxaliplatin + gimeracil/oteracil/tegafur
DOI:
10.1186/s12885-021-08459-3
Source:
Title:
Conversion therapy using S1/paclitaxel chemotherapy plus apatinib in unresectable gastric cancer: Updated data from a phase II trial.
Published date:
05/16/2018
Excerpt:
Patients (pts) with histologically proved unresectable, HER-2 negative, advanced GC were recruited to receive 2 cycles of S1/paclitaxel chemotherapy (S1: 60 mg, oral, bid for 2 weeks followed by a drug-free interval of 1 week; paclitaxel: 150 mg/m2, iv, 3 h, on day 1) plus apatinib (500 mg, oral, qd) and 1 cycle of S1/paclitaxel prior to radical surgery... The overall response rate was 73.3% (22 partial response [PR]), and a disease control rate was 93.3% (22 PR and 6 stable disease)...Combination of apatinib with S1/paclitaxel chemotherapy shows clinical benefits in unresectable GC, with acceptable safety profile and long survival.
Secondary therapy:
paclitaxel + gimeracil/oteracil/tegafur
DOI:
10.1200/JCO.2018.36.15_suppl.e16010
Trial ID:
